30 closest matches · ranked by relevance
HIV · Sexually Transmitted Diseases · HIV Infections
Primary: Number of Sexual Partners, 3 Months Post Intervention — 2.19; 2.04; 2.14; 2.13 number of partners
Gonorrhea · Chlamydia
Primary: GC/CT Detection Rates — 15.2; 12.1; 11 No. of patients with positive GC/CT
HIV Infections · Sexually Transmitted Diseases
Primary: Efficacy of Internet-based Program for Increasing Condom Use With Non-main Sex Partners — .68; .56 percentage of sex acts protected by cond
HIV Infections
Primary: Measurement of Acceptance Rate of PrEP — 921; 557 Participants
Penicillin Allergy
Primary: Number of Respondents Who Responded YES to Any Question Defining High Risk Penicillin Allergy Using Questionnaire Developed by the Study — 36; 36 Participants
Uterine Cervical Neoplasms · Sexually Transmitted Diseases
Primary: Concordance Between Vaginal Self-swab Results and Provider-collected Cervical Swab Results for HPV DNA Among Sexually Active FTM Adults — 15; 2; 6; 108 Participants…
HIV/AIDS · Sexually Transmitted Infections
Primary: STI Incidence — 250; 226 participants
Sexually Transmitted Diseases · Gonorrhea · Chlamydia
Primary: Number of Participants That Schedule a Pre-test Session — 74 Participants
Bacterial Vaginosis
Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…
Gonorrhea · Chlamydia · Syphilis
Primary: Number of Quarterly Visits In Which an STI Was Detected — 61; 82; 36; 39 No. quarterly visits with STI event
Sexually Transmitted Infection
Primary: Doxycycline Concentration in Rectal Tissue — 2.330 µg/g
Teen Sexual Health
Primary: Dual Protection Behaviors, Reported in Surveys and Reviewed in the Medical Record. — 7; 6; 8; 8 Participants
Urethritis · Cervicitis · Sexually Transmitted Infections
Primary: Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis — 7; 1 Antibiotic days of therapy (DOT) — p=0.053
Hepatitis B Virus
Primary: Mean Number of Doses of HBV Vaccine Received — .78; .85; .94; .98 Doses of HBV Vaccine — p==.885
Exposure to Sexually Transmissible Disorder (Event)
Primary: Feasibility as Assessed by the Number of Participants Who Are Enrolled With a Partner — 17; 17 Participants
Self Efficacy · HIV Prevention · STI Prevention
Primary: Change in Prevention Self-efficacy — 1.87; 0.20 score on a scale — p=0.04
Gonorrhoea
Primary: Microbiological Efficacy of Gentamicin and Azithromycin for the Treatment of Uncomplicated Gonococcal Infection — 100 percentage of participants — p=<0.05
Human Papillomavirus Infection
Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale
HIV Infections · HIV/AIDS · Neisseria Gonorrheae Infection
Primary: Incidence of N. Gonorrhoeae, C. Trachomatis, or Early Syphilis Infection by Laboratory-based Diagnosis — 25.1; 29.0 Events per 100 person-years
Chlamydial Infection
Primary: Assess Microbiological Failure of Recommended Azithromycin and Doxycycline Regimens in Uncomplicated Chlamydia Trachomatis Infection in a Setting Where Repeat Exposure…
HIV Infections
Primary: Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms — 0.07; 1.03 event rate per 100 person-yr — p=<0.0001
Sexually Transmitted Diseases
Primary: Rectal Doxycycline Concentration — 0.654 µg/g
Syphilis
Primary: Treatment Success Defined as a Decrease in Rapid Plasma Reagin (RPR) Titer of >= 2 Dilutions (4-fold) — 27; 28 participants
HIV Infections · Sexually Transmitted Diseases · Pregnancy
Primary: Initiation of Sexual Intercourse — 308; 509 participants
HIV Infections
Primary: HIV Incidence at the Community Level — 1.49; 2.04 HIV infections per 100 person-years
HIV Infections · Sexually Transmitted Diseases, Viral · Syphilis
Primary: The Number of Participants Who Are Able to Self-administer the DPP® HIV-Syphilis Test With mLab App Plus — 12 Participants
Anal Chlamydia Infection
Primary: The Proportion of Subjects With Microbiologic Cure (Negative Rectal CT NAAT Result) at Day 29 — 0.74; 1.00 proportion of participants — p=<0.001
Sexually Transmitted Diseases · Gonorrhea · Chlamydia
Primary: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups — 684; 696 Participants
Contraception Behavior
Primary: Number of Eligible Participants Who Agreed to be Enrolled in the Study — 119 participants
STI
Primary: doxyPEP DOT Adherence — 1417 Doses